Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

Novo Nordisk is making moves to retain its market share in the weight loss space after Eli Lilly's tirzepatide won a ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

You’ve probably familiar with the abs muscles—the ones you see poppin' on sculpted celebs like J.Lo or Halle Berry, but there’s way more to core strength than those visible six-pack muscles.

RayzeBio, the radiopharmaceutical unit of Bristol Myers Squibb, licensed an experimental drug and diagnostic agent for prostate cancer from Philochem AG for a $350 million upfront payment. Philochem ...

Deep Apple collaborates with Novo Nordisk to discover and develop oral therapeutics for cardiometabolic diseases: South San Francisco, California Thursday, June 12, 2025, 18:00 Hr ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Deep Apple Therapeutics, Inc. has announced a research collaboration and exclusive worldwide license agreement with Novo ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk ...

Danish pharma major Novo Nordisk and privately-held Californian firm Deep Apple Therapeutics have announced a research ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Novo Nordisk and Deep Apple Therapeutics Inc. have entered a research collaboration and exclusive license agreement.